-
Je něco špatně v tomto záznamu ?
Pilot study of A-FABP levels as a predictive factor of SPECT results in asymptomatic relatives of patients with cardiovascular disease
E. Sovová, J. Vrbková, D. Stejskal, M. Kamínek, I. Metelková, M. Budikova, M. Kaletová, M. Sova, M. Sovová,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2007-06-01 do 2021-01-31
Health & Medicine (ProQuest)
od 2007-06-01 do 2021-01-31
Public Health Database (ProQuest)
od 2007-06-01 do 2021-01-31
PubMed
25123032
DOI
10.2217/bmm.13.160
Knihovny.cz E-zdroje
- MeSH
- asymptomatické nemoci * MeSH
- dospělí MeSH
- jednofotonová emisní výpočetní tomografie * MeSH
- kardiovaskulární nemoci * MeSH
- lidé středního věku MeSH
- lidé MeSH
- pilotní projekty MeSH
- proteiny vázající mastné kyseliny krev MeSH
- rodokmen * MeSH
- senioři MeSH
- vápník krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: A-FABP is a promising link between metabolic syndrome and atherosclerosis. It is not well known whether level of A-FABP predicts results of SPECT. PATIENTS & METHODS: In 82 subjects (53 males) with a median age of 54 years, who were first-degree relatives of patients with cardiovascular disease, the following tests and examinations were performed: A-FABP, calcium score (CS) and SPECT. RESULTS: Subjects with positive and negative SPECT results differed significantly in the noncategorized CS (p = 0.001), uric acid (p = 0.025) and the total cholesterol:high-density lipoprotein ratio (p = 0.043), but not in other parameters (including A-FABP). To predict SPECT results, the best model proved to be a logistic regression model with gender and noncategorized CS as predictors, with an area under the receiver operating characteristic curve of 0.89 (the sensitivity and specificity based on a CS cutoff of 11.1 were 77.78 and 75.34%, respectively). CONCLUSION: The serum level of A-FABP is not a predictor of a positive SPECT result.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031909
- 003
- CZ-PrNML
- 005
- 20180514142253.0
- 007
- ta
- 008
- 151005s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/bmm.13.160 $2 doi
- 035 __
- $a (PubMed)25123032
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sovová, E $u Department of Internal Medicine I - Cardiology, Faculty of Medicine & Dentistry, Palacký University Olomouc & University Hospital Olomouc, Olomouc, Czech Republic.
- 245 10
- $a Pilot study of A-FABP levels as a predictive factor of SPECT results in asymptomatic relatives of patients with cardiovascular disease / $c E. Sovová, J. Vrbková, D. Stejskal, M. Kamínek, I. Metelková, M. Budikova, M. Kaletová, M. Sova, M. Sovová,
- 520 9_
- $a BACKGROUND: A-FABP is a promising link between metabolic syndrome and atherosclerosis. It is not well known whether level of A-FABP predicts results of SPECT. PATIENTS & METHODS: In 82 subjects (53 males) with a median age of 54 years, who were first-degree relatives of patients with cardiovascular disease, the following tests and examinations were performed: A-FABP, calcium score (CS) and SPECT. RESULTS: Subjects with positive and negative SPECT results differed significantly in the noncategorized CS (p = 0.001), uric acid (p = 0.025) and the total cholesterol:high-density lipoprotein ratio (p = 0.043), but not in other parameters (including A-FABP). To predict SPECT results, the best model proved to be a logistic regression model with gender and noncategorized CS as predictors, with an area under the receiver operating characteristic curve of 0.89 (the sensitivity and specificity based on a CS cutoff of 11.1 were 77.78 and 75.34%, respectively). CONCLUSION: The serum level of A-FABP is not a predictor of a positive SPECT result.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a asymptomatické nemoci $7 D058070
- 650 _2
- $a vápník $x krev $7 D002118
- 650 12
- $a kardiovaskulární nemoci $7 D002318
- 650 _2
- $a proteiny vázající mastné kyseliny $x krev $7 D050556
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a rodokmen $7 D010375
- 650 _2
- $a pilotní projekty $7 D010865
- 650 12
- $a jednofotonová emisní výpočetní tomografie $7 D015899
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vrbková, J
- 700 1_
- $a Stejskal, D
- 700 1_
- $a Kamínek, M
- 700 1_
- $a Metelková, I
- 700 1_
- $a Budikova, M
- 700 1_
- $a Kaletová, M
- 700 1_
- $a Sova, M
- 700 1_
- $a Sovová, Markéta $7 xx0224226
- 773 0_
- $w MED00172897 $t Biomarkers in medicine $x 1752-0371 $g Roč. 8, č. 5 (2014), s. 633-40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25123032 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20180514142426 $b ABA008
- 999 __
- $a ok $b bmc $g 1092785 $s 915035
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 8 $c 5 $d 633-40 $i 1752-0371 $m Biomarkers in medicine $n Biomark Med $x MED00172897
- LZP __
- $a Pubmed-20151005